Cormorant Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Cormorant Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-50,000	Closed	-$1.13M	–	66
2014 Q2	$1.13M	Sell	50,000 -250,000	-83%	-$5.22M	0.3%	51
2014 Q1	$7.3M	Sell	300,000 -500,000	-63%	-$12.6M	1.68%	26
2013 Q4	$20M	Buy	+800,000	New	+$18.9M	5.8%	7

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cormorant Asset Management's ACAD Position: Q3 2014 in Review

Cormorant Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2014, closing a stake of 50,000 shares — an estimated $1.13M sold.

Cormorant Asset Management first reported a position in ACAD in Q4 2013 and held it in 3 quarters. The position peaked at $20M in Q4 2013. 162 funds tracked by Wall St. Rank hold ACAD as of Q3 2014.

Cormorant Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
Cormorant Asset Management sold 50,000 Acadia Pharmaceuticals shares in Q3 2014, an estimated $1.13M.
Cormorant Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 3 quarters.
Cormorant Asset Management's Acadia Pharmaceuticals position peaked at $20M in Q4 2013.
162 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2014.

Based on Cormorant Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.